Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Cash from Financing Activities: 2017-2025

Historic Cash from Financing Activities for Denali Therapeutics (DNLI) over the last 9 years, with Sep 2025 value amounting to -$778,000.

  • Denali Therapeutics' Cash from Financing Activities rose 95.81% to -$778,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$7.1 million, marking a year-over-year decrease of 101.44%. This contributed to the annual value of $484.3 million for FY2024, which is 2617.76% up from last year.
  • Latest data reveals that Denali Therapeutics reported Cash from Financing Activities of -$778,000 as of Q3 2025, which was down 147.94% from $1.6 million recorded in Q2 2025.
  • In the past 5 years, Denali Therapeutics' Cash from Financing Activities registered a high of $500.3 million during Q1 2024, and its lowest value of -$18.6 million during Q3 2024.
  • Moreover, its 3-year median value for Cash from Financing Activities was $1.6 million (2025), whereas its average is $45.4 million.
  • Over the last 5 years, Denali Therapeutics' Cash from Financing Activities had its largest YoY gain of 31,089.21% in 2024, and its largest YoY loss of 844.74% in 2024.
  • Over the past 5 years, Denali Therapeutics' Cash from Financing Activities (Quarterly) stood at $5.2 million in 2021, then soared by 5,698.20% to $299.7 million in 2022, then slumped by 98.43% to $4.7 million in 2023, then plummeted by 188.59% to -$4.2 million in 2024, then surged by 95.81% to -$778,000 in 2025.
  • Its Cash from Financing Activities stands at -$778,000 for Q3 2025, versus $1.6 million for Q2 2025 and -$3.8 million for Q1 2025.